There’s No Lab Test for Depression—But a Landmark Study Aims To Change This
Data from thousands of patients will be analyzed across several years to take the guesswork out of psychiatry.
Marty Parrish, 63, a patient spokesperson, remembered experiencing his first major bout of depression at age 17.
“That first episode was so severe that I couldn’t get out of bed for three days,” he said.
At the time, Marty had just moved away from his family to work with a church youth group. What would be a positive milestone for many—flying the nest—can overwhelm the brain for others.
A change in circumstances or a stressful life event are among many things that can trigger depression; an individual’s genetics, brain chemistry, underlying medical conditions, among many other factors, are all considered determinants of whether someone will develop the condition.
Globally, it is estimated that over 5% of adults live with depression; that’s 1 in every 20.
Marty turned to self-medicating with alcohol before seeking professional treatment. First-line medications have proven valuable for many and initially seemed to work for him.
“Though it took nearly six weeks for the [first] medication to work, the difference to me was like turning on a light in a dark room.” — Marty Parish, patient spokesperson.
Despite a seemingly positive start, Marty would go on to cycle through different medications, alternating between “periods of depression and wellness” to avoid side effects and cope with both the financial and psychological burden of his diagnosis. “In some ways, the knowledge that I needed an antidepressant, and one with intolerable side effects to me, was itself depressing,” he said.
Marty continued this cycle until 2014, when he first discovered transcranial magnetic stimulation (TMS), which has made a permanent difference in his struggle against depression.
“It is only because of the continued research into depression that newer treatments have been found that offer new hope to many who experience depression as I have… My story is just one of millions of examples,” he reflected.
Stories like Marty’s have inspired a new initiative, led by the Foundation for the National Institutes of Health (FNIH): the Multi-Modal Assessment and Phenotyping in Depression (MAP-D) project. Through bringing together academics, patient advocates, philanthropists, and drug developers, the program aims to create “the most comprehensive depression dataset in history.”
A landmark, multi-year observational study will profile thousands of individuals with depression, bringing together genomics, neuroimaging, clinical assessments, and patient-reported outcomes to identify biomarkers that can guide drug development and personalize depression care.
Why has psychiatry lacked major therapeutic advances?
The first antidepressants were discovered by accident, when clinicians noticed that a tuberculosis drug, iproniazid, lifted the mood of patients.
Later classes, including tricyclic antidepressants (TCAs), targeted monoamine neurotransmission, the same pathway that had been discovered by chance.
Marty was one of many patients who received a TCA in the 1980s and was also one of many who would face severe side effects. “After three months of treatment, the side effects became intolerable, and I dropped the medication,” he recalled.
The intended effect of TCAs was to modulate the reuptake of neurotransmitters involved in mood, but the class was later found to affect many other receptors, leading to a myriad of adverse effects. TCAs now sit under the “dirty drug” umbrella; they are still used in depression but are not the first class that clinicians would typically prescribe.
Today, first-line options include sertraline and fluoxetine, serotonin reuptake inhibitors (SSRIs) that increase serotonin availability in the brain to lift mood. Nearly one in three patients do not respond to these “newer” medications, both approved circa 1990.
“Depression, or major depressive disorder, is a biologically and clinically heterogeneous disease, with wide variability in symptoms, comorbidities, and treatment responses,” commented Steve Hoffmann, senior vice president (SVP) and chief preclinical officer (CPO) at the FNIH, when asked why drug development for depression has stagnated.
If the heterogeneous etiology of depression was not already complex enough, it has been further complicated by the discovery of “biotypes,” or clinically distinct types of depression that seem to change how individuals respond to treatment.
Hoffmann also highlighted a lack of reliable biomarkers as a contributor to the lack of advancement in the field: “Without these biomarkers, clinicians have limited tools and ability to identify specific depression subtypes (or phenotypes) and predict which treatment will work best for a given patient.”
“Overall, though progress has been made, it is still very little compared to the strides made in cancer research and other major illnesses,” Marty reflected.
Through the MAP-D project, researchers aim to change this. In the first three years of the program alone, $22 million has been committed to funding depression research.
Using biomarkers to guide precision psychiatry
The field of oncology benefits from a range of biomarkers: an individual’s cancer risk can be determined through genetic testing, circulating blood-based biomarkers can be used for screening, even staging, and tumor-specific biomarkers can provide insights into treatment response.
Across other indications, blood tests can indicate infection, autoimmune disease, and even whether someone has had a heart attack.
Yet for depression, no single biomarker has been validated for routine clinical use.
Hoffmann put this into perspective: “Depression involves complex interactions among brain circuits, neurotransmitters, hormones, immune responses, genetics, and environmental and social influences. Understanding these interacting systems is far more difficult than studying a disease that primarily affects a single organ or pathway.”
“These factors interact with biology in different ways for different people, making it harder to identify a common biological signature or treatment target.”
This challenge is exactly what the MAP-D project aims to overcome.
“MAP-D is designed to address the root causes of poor outcomes in depression research.” — Steve Hoffmann, SVP and CPO at the FNIH.
MAP-D will integrate data from clinical assessments, patient-reported outcomes, and advanced technologies, including AI, to create a comprehensive dataset.
The MAP-D plan
- Years 1–3: Phase 1a, currently in progress, is recruiting 300 participants worldwide with moderate to severe depression.
- Years 4–7: Phase 1b is conducted, with expansion to 2,500 participants.
- Years 8–12: Continued development of the dataset.
The end dataset will encompass genomics, neuroimaging, biological assays, electroencephalograms, sleep monitoring, digital phenotyping (speech and facial recognition), clinical assessments, and patient-reported outcomes.
“For years, depression has been treated as a single illness. We know depression symptoms can look different from person to person and can be accompanied by related conditions,” noted Hoffmann.
“A deeper understanding and multimodal assessment that defines the different forms of depression can help identify biologically distinct subtypes and move treatment from a one-size-fits-all approach toward precision-driven care that delivers the right treatment to the right patient at the right time.” — Steve Hoffmann, SVP and CPO at the FNIH.
“Combined with advanced AI analytics, these multimodal longitudinal data can identify biologically meaningful patient phenotypes that power trials and predict treatment responses,” he added.
The importance of patient experience in psychiatric research
Often, depression doesn’t present in isolation; many patients face comorbid psychiatric conditions. One study found that almost three out of four patients with depression had at least one comorbid psychiatric condition, with anxiety disorders accounting for half of those cases.
“Historically, many depression studies excluded patients with general anxiety, bipolar spectrum disorders, post-traumatic stress disorder (PTSD), substance use disorders, chronic medical illnesses, or other co-occurring mood or behavioral conditions to reduce variability,” Hoffmann pointed out.
“While this may improve experimental controls, it creates study populations that differ substantially from real-world clinical populations. As a result, treatments that appear effective in tightly controlled trials may perform differently in true clinical practice.”
MAP-D is approaching psychiatric research differently and will not exclude conditions that frequently occur alongside depression, such as PTSD and bipolar disorder.
“This creates the opportunity to develop treatment-matching tools that work across the diverse patient populations, including those with multiple co-occurring conditions,” Hoffmann noted, adding that any biomarkers or predictive tools identified through the MAP-D cohort should be more applicable to the general population.
Marty is keen to participate in the program; his motivation to engage in advocacy was sparked several years ago when he observed the stigma around mental health.
“2019 was the milestone year for my engagement. Early that year, Peggy [my wife] and I attended a town hall meeting about an inpatient mental health facility located in a suburban community. The negativity and hostility expressed by neighbors of the proposed facility shocked us both and inspired me to share my story.”
Marty continued to use his voice to educate others and share the reality of living through mental health struggles, later teaching medical students, clinicians, and state institution staff.
“What motivated me to contribute to the MAP-D program is the hope it will help answer some of the most frustrating questions surrounding depression, including what causes it, how it can be diagnosed more accurately, and how treatment can be made more effective,” he commented.
“It is way past time for a major investment in research to tackle a medical condition that is a major cause of absenteeism and lack of productivity in the workplace, not to mention the misery and death it brings to millions of patients and families,” Marty shared with Technology Networks.
The impact of depression is far-reaching
- In society and the workplace: Depression is classed as a leading public health crisis and a driver of economic loss. The World Health Organization estimates that depression and anxiety, together, account for the loss of ~12 billion working days each year.
- In the home: Depression can strain relationships and impact the entire family, as well as contribute to financial stress if individuals cannot work.
- For the individual: The burden of depression on the individual living with it has been difficult to quantify, but it is multi-layered, impacting all aspects of life from physical health to relationships and daily functioning.
Defining success in psychiatric care
When asked what success following MAP-D would look like, Hoffmann was clear on the end goal:
“MAP-D will have succeeded if it delivers validated biological tools and disease phenotypes that can be broadly adopted in clinical trials, improve patient stratification, guide treatment selection, and accelerate the development of more precise and effective therapies for depression.”
“MAP-D won't solve every unanswered question in neuropsychiatry overnight, but it can help us move beyond trial-and-error treatment toward more precise, data-informed care,” he continued.
“More broadly, I hope success will enable our partners and mental health ecosystem to reflect and say that MAP-D demonstrated the power of the public–private partnership model.”
More than 20 academic institutions, 19 private-sector businesses, and 3 major public-sector organizations, including the US Food and Drug Administration, have already helped shape the initiative. By bringing these groups together, Hoffmann hopes that the program can achieve progress that “no single organization could have achieved on its own.”
“Finally, the measure of success is whether patients benefit,” Hoffmann concluded.
Marty echoed this sentiment: “I am hopeful that MAP-D will result in answers and advances that are sorely needed. I'd like to remind others that the work that MAP-D is doing can mean the difference between life and death for many people.”